Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 3/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11744305 | 0.78 | S1PR2 (0.40) | XDHCSNK1A1CLK4SYKAURKA | |
| SCHEMBL20157281 | 0.74 | MEN1 (0.39) | XDHSYKEGFRERBB2ABL1 | |
| SCHEMBL27953801 | 0.74 | AR (0.53) | AR | |
| SCHEMBL7875292 | 0.74 | MAP2K1 (0.44) | EGFRERBB2ALDH1A1SRCMAP2K1 | |
| SCHEMBL8081930 | 0.74 | MAPK1 (0.38) | XDHALDH1A1AR | |
| SCHEMBL12466724 | 0.74 | MEN1 (0.35) | XDHCSNK1A1CLK4SYKAURKA | |
| SCHEMBL7765659 | 0.72 | SNCA (0.43) | XDHSNCAAR | |
| SCHEMBL14379734 | 0.71 | ALDH1A1 (0.50) | ALDH1A1NPSR1TDP1ADORA2AADORA1 | |
| SCHEMBL29878757 | 0.70 | AR (0.44) | AR | |
| SCHEMBL5017573 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3563856-B1 | PHARMACEUTICAL COMPOSITION COMPRISING CAPECITABINE, GIMERACIL, AND OTERACIL FOR TREATING CANCER AND USE THEREOF | CHEN XIAOHUA (CN) | 2020-11-04 | — | — | EP | disclosed |
| EP-3563856-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND USE THEREOF | Chen, Xiaohua (CN) | 2019-11-06 | — | — | EP | disclosed |
| CN-106619689-B | It is a kind of for the pharmaceutical composition for the treatment of cancer, kit and its application | 陈晓华 | 2018-05-01 | — | — | CN | disclosed |
| CN-106619689-A | Medicine composition and kit for therapy of cancer and application thereof | 陈晓华 | 2017-05-10 | — | — | CN | disclosed |
| EP-1750703-B1 | METHOD FOR REDUCING GASTROINTESTINAL TOXICITY DUE TO THE ADMINISTRATION OF TEGAFUR | TAIHO PHARMACEUTICAL CO LTD (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-20080166427-A1 | Method for Reducing Gastrointestinal Toxicity Due to the Administration of Tegafur | TAIHO PHARMACEUTICAL CO., LTD (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1750703-A4 | METHOD FOR REDUCING GASTROINTESTINAL TOXICITY DUE TO THE ADMINISTRATION OF TEGAFUR | TAIHO PHARMACEUTICAL CO LTD (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20070238767-A1 | Thiazoline acid derivatives | FOUNDATION, INC. (US) | 2007-10-11 | — | — | US | disclosed |
| EP-1750703-A1 | METHOD FOR REDUCING GASTROINTESTINAL TOXICITY DUE TO THE ADMINISTRATION OF TEGAFUR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005105086-A1 | METHOD FOR REDUCING GASTROINTESTINAL TOXICITY DUE TO THE ADMINISTRATION OF TEGAFUR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-10 | — | — | WO | disclosed |
| EP-0543015-B1 | COMPOSITION, METHOD AND KIT FOR POTENTIATING ANTITUMOR ACTIVITY AND FOR CURING TUMOR | TAIHO PHARMACEUTICAL CO LTD (JP) | 1998-11-11 | — | — | EP | disclosed |
| US-5525603-A | MIXTURE OF 2,4-DIHYDROXYPYRIDINE COMPOUND AND OXONIC ACIDADMINISTERED WITH TEGAFUR; SIDE-EFFECT REDUCTION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1996-06-11 | — | — | US | disclosed |
| EP-0543015-A1 | COMPOSITION, METHOD AND KIT FOR POTENTIATING ANTITUMOR ACTIVITY AND FOR CURING TUMOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1993-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238767-A1 | Thiazoline acid derivatives | SLC30A5, SLC30A7, SLC39A7 | XDH 157/4885CSNK1A1 3957/4885CLK4 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.